Drug Profile

SNS 812

Alternative Names: Inhaled MBS-COV - Oneness Biotech; MBS-COV; SNS-812

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oneness Biotech
Class Antivirals; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II COVID 2019 infections

Most Recent Events

16 May 2025 SNS 812 is available for licensing as of 16 May 2025
25 Sep 2024 Oneness Biotech completes phase-II clinical trials in COVID-2019 infections in USA and Taiwan (Inhalation) (NCT05941793)
11 Sep 2024 Phase-II clinical trials in COVID-2019 infections in USA (Inhalation) (NCT05941793)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com